ВОЗМОЖНОСТИ МЕДИКАМЕНТОЗНОГО ТРОМБОЛИЗИСА В ЛЕЧЕНИИ ПАЦИЕНТОВ С ИШЕМИЧЕСКИМ ИНСУЛЬТОМ
- Авторы: Домашенко МА1, Максимова МЮ1, Суслина ЗА1, Domashenko MA2, Maximova MY.2, Suslina ZA2
-
Учреждения:
- Научный центр неврологии РАМН, Москва
- Выпуск: № 7 (2009)
- Страницы: 38-42
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/276799
- ID: 276799
Цитировать
Полный текст
Аннотация
Об авторах
М А Домашенко
Научный центр неврологии РАМН, МоскваНаучный центр неврологии РАМН, Москва
М Ю Максимова
Научный центр неврологии РАМН, МоскваНаучный центр неврологии РАМН, Москва
З А Суслина
Научный центр неврологии РАМН, МоскваНаучный центр неврологии РАМН, Москва
M A Domashenko
M Yu Maximova
Z A Suslina
Список литературы
- Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М., 2001.
- Инсульт. Диагностика, лечение и профилактика. Руководство для врачей / Под ред. З.А. Суслиной, М.А. Пирадова. М., 2008.
- Очерки ангионеврологии / Под ред. З.А. Суслиной. М., 2005.
- Rha J-H, Saver JL. The Impact of Recanalization on Ischemic Stroke Outcome. A Meta-Analysis. Stroke 2007;38:967-73.
- The Multicenter Acute Stroke Trial-Europe (MAST-E) Study Group. Thrombolytic therapy with Streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-50.
- The Multicentre Acute Stroke Trial-Italy (MAST-I) Study Group. Randomised controlled trial of Streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet 1995;346:1509-14.
- Donnan GA, et al. for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-66.
- Hacke W, et al., for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
- The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-87.
- Hacke W, et al. Randomized double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
- Clark WM. Recombinant Tissue-Type Plasminogen Activator (Alteplase) for Ischemic Stroke 3 to 5 Hours After Symptom Onset. The ATLANTIS Study: A Randomized Controlled Trial. JAMA 1999;282(21):2019-26.
- Wardlaw JM, et al. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev 2003:CD000213.
- Hacke W, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
- Hacke W, et al. Thrombolysis with Alteplase 3 to 4.5 hours after acute ischemic stroke. NEJM 2008;359(13):1317-29.
- Wahlgren N, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Trrombolysis in Stroke-Monitoring Study (SIST-MOST): an observational study. Lancet 2007;369:275-82.
- Guidelines for Management of Ischaemic Stroke of the European Stroke Organisation, 2008 http://www.eso-stroke.org/recommendations.
- Adams H, et al. Guidelines for the management of adults with ischemic stroke. Stroke 2007;38:1655-711.
- Wardlaw C, Wardlaw J. Therapeutic thrombolysis for acute ischaemic stroke. BMJ 2003 (1);326(7383):233-34.
- Molina CA, et al. Thrombolysis-related hemorrhagic infarction. A marker of early reperfusion, reduced infarct size, and improved outcome in patients with proximal middle cerebral artery occlusion. Stroke 2002;33:1551-56.
- Lansberg MG, et al. Risk factors of symptomatic intracerebral hemorrhage after tPA therapy for acute stroke. Stroke 2007;38:2275-78.
- Пирадов М.А. Интенсивная терапия инсульта: взгляд на проблему // Анналы клинической и экспериментальной неврологии. 2007. № 1. С. 17-22.
- Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59(6):862-67.